期刊文献+

ERCC1和PKCalpha在非小细胞肺癌中的表达及其临床意义 被引量:2

The Clinical Signifcance of Expression of ERCC1 and PKCalpha in Non-small Cell Lung Cancer
下载PDF
导出
摘要 背景与目的剪切修复偶联因子1(Excision-Repair Cross-Complementing 1,ERCC1)是核苷酸外切修复家族中的重要成员,它在核酸损伤修复过程和凋亡过程中起着重要作用。蛋白激酶C-α(Protein kinase Calpha,PKCα)是蛋白激酶C(PKC)的一种同工酶,PKCα调控细胞的转化和增殖,是肿瘤细胞中重要的信号途径。本研究初步探索ERCC1和PKCα在非小细胞肺癌(non-small cell lung cancer,NSCLC)中表达所代表的临床意义。方法运用免疫组化方法检测51例NSCLC组织、21例癌旁组织中ERCC1和PKCα的表达,并采用SPSS13.0软件进行相关统计分析。结果ERCC1和PKCα在肿瘤组阳性率明显高于癌旁组(Ρ<0.05);ERCC1与临床分期和N分期等因素有关,临床III+IV期及N1-2期患者ERCC1阳性率要分别高于I+II期和N0期患者(Ρ=0.011,P=0.015);ERCC1阴性组的5年生存时间高于阳性组(Ρ<0.05);Spearman相关分析提示ERCC1与PKCα之间存在正相关(r=0.425,P=0.002)。结论ERCC1和PKCα可能与NSCLC的发生相关,ERCC1可能与肿瘤的预后相关。ERCC1和PKCα之间可能存在共同作用通路。 Background and objective Excision repair cross-complementing 1 (Excision-Repair Cross-Complementing 1, ERCC1), an important member of the DNA repair gene family, plays a key role in nucleotide excision repair and apoptosis of tumor cells. Protein kinase C-α (Protein kinase C, PKCα), an isozyme in protein kinase C family, is an important signaling molecule in signal transduction pathways of tumors, which has been implicated in malignant transformation and proliferation. The aim of this study was to explore the clinical significance of ERCC1 and PKCα in non-small cell lung cancer (NSCLC). Methods The expression of ERCC1 and PKCα were examined by immunohistochemistry (IHC) in the specimens of 51 cases of NSCLC patients tissue and 21 cases of paracancerous tissue. The relationship between detected data and patients′ clinical parameters was analyzed by SPSS 13.0 software. Results The positive expression rate of ERCC1 and PKCα in NSCLC tissues was significantly higher than paracancerous tissues (P〈0.05. Expression of ERCC1 was closely related to clinical stage and N stage. The positive rate of ERCC1 was higher in III+IV or N1+N2 stage patients compared with I+II or N0 stage (Ρ=0.011, P=0.015). We also found that 5-year survival of negative group of ERCC1 was remarkably higher than that of positive group by χ^2 test (P〈0.05. Expression of ERCC1 was positively correlative to PKCα by Spearman′s correlation analysis (r=0.425, P=0.002) in NSCLC. Conclusion The results suggest ERCC1 and PKCα might be correlated with the development of NSCLC. ERCC1 might be related to prognosis of NSCLC. There might be existed a mechanism of coordination or regulation between ERCC1 and PKCα.
出处 《中国肺癌杂志》 CAS 2010年第3期270-273,共4页 Chinese Journal of Lung Cancer
关键词 肺肿瘤 预后 ERCC1 蛋白激酶C-Α 免疫组织化学 Lung neoplasms Prognosis ERCC1 protein human Protein kinase C-alpha Immunohistochemistry
  • 相关文献

参考文献15

  • 1Wachters FM, Wong LS, Timens W, et al. ERCC 1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage Ill/IV NSCLC patients treated with chemotherapy. Lung Cancer, 2005, 50(2):211-219.
  • 2许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,1996,6(4):229-231. 被引量:1365
  • 3Taillade L, Penault-Llorca E Boulet T, et al. Immunohistochemichal expres- sion of biomarkers: a comparative study between diagnostic bronchial biop- sies and surgical specimens of non-small-cell lung cancer. Ann Oncol, 2007, 18(6): 1043-1050.
  • 4Takenaka T, Yoshino I, Kouso H, et al. Combined evaluation of Rad51 and ERCC 1 expressions for sensitivity to platinum agents in non-sman cell lung cancer. IntJ Cancer, 2007, 121 (4): 895-900.
  • 5Kwon HC, Roh MS, Oh SY, et al. Prognostic value of expression of ERCC1 thymidylate synthase, and glutathione S-transferase P 1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol, 2007, 18(3) 504-509.
  • 6Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non- small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med, 2006, 355(10): 983-991.
  • 7Smith S, Su D, Rigault de la Longrais IA, et al. ERCCI genotype and pheno- type in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J Clin Oncol, 2007, 25(33): 5172-5179.
  • 8Bellmunt J, Paz-Ares L, CueUo M, et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin- based chemotherapy. Ann Oncol, 2007, 18(3): 522-528.
  • 9Ceppi P, Volante M, Novello S, et al. ERCC1 and RRMI gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol, 2006, 17(12): 1818-1825.
  • 10Zheng Z, Chen T, Li X, et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N EnglJ Med, 2007, 356(8): 800-808.

二级参考文献16

共引文献1368

同被引文献9

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部